Sertraline vs. Citalopram: Depression, Anxiety, Heart Safety and Withdrawal

Both medicines affect serotonin reuptake. That mechanism describes part of their pharmacology, not a test showing that an individual has a serotonin deficiency. Their benefits are assessed through symptoms and functioning over time, rather than an immediate feeling after the first tablet. Neither should be treated as an as-needed sedative for a difficult moment.

Sertraline is sold under names including Zoloft and Lustral; citalopram may be known as Celexa or Cipramil. Names and formulations differ by country. The separate sertraline and citalopram profiles provide more detailed medicine-specific information. [1] [2]

Sertraline has treatment roles that include depression, OCD, panic disorder, PTSD and social anxiety. Citalopram is used for depression and panic disorder in UK patient information. US approvals and age indications are not identical to UK practice. Do not assume that every indication for one SSRI applies to every other SSRI. [3] [2]

A clinician may sometimes propose an off-label use. That should be accompanied by an explanation of the supporting evidence, alternatives and intended benefit. Ask which condition is being treated when symptoms overlap. For example, a plan for persistent depression is not necessarily the same as a plan for OCD, panic or trauma-related symptoms.

Citalopram can prolong the QT interval, part of the heart’s electrical cycle, in a dose-dependent way. Risk assessment includes pre-existing rhythm problems, certain cardiac conditions, low potassium or magnesium and other QT-prolonging medicines. The MHRA describes dose restrictions and monitoring considerations for citalopram and escitalopram. [4]

This does not mean everyone taking citalopram needs to stop or will develop an arrhythmia. It means the prescriber should assess the relevant risks. Fainting, palpitations with dizziness or a seizure should not be dismissed as anxiety. An electrocardiogram and blood tests may be needed depending on the clinical circumstances.

NHS Specialist Pharmacy Service identifies sertraline as a first-line antidepressant option in coronary heart disease, while citalopram is less preferred and may require additional precautions when used. This is a condition-specific prescribing consideration, not proof that sertraline is risk-free or the correct choice for every person. [5]

The entire medicine list still matters. Anticoagulants, antiplatelet treatment and painkillers can alter bleeding risk with SSRIs. A person doing well on an established prescription should discuss relevant new cardiac information with the prescriber rather than interpret a general comparison as an instruction to change immediately.

Both medicines can cause digestive symptoms, headaches, sleep changes, sweating and sexual difficulties. Individual patterns differ. Some early effects settle, while others persist or become important only after daily routines resume. Report side effects that interfere with eating, work, relationships or the ability to continue treatment. [1] [2]

A useful record separates the symptom from its interpretation. Write what happened, when it began, the actual medicine taken and what changed in daily life. Saying that nausea prevented breakfast is more informative than deciding independently that the medicine is toxic. Serious symptoms are the exception: seek help promptly rather than waiting to complete a diary.

Sexual side effects can be difficult to raise, but they are a legitimate part of a medication review. Depression and anxiety can also affect desire, arousal and relationships. Discuss the timing rather than assuming every difficulty comes from the medicine or, conversely, dismissing a new problem as the original illness.

Similarly, changes in appetite, weight or the sense of emotional responsiveness deserve individualized assessment. There is no reliable promise that switching between these two medicines will resolve a particular symptom. The sexual side-effects guide explains how to prepare a focused discussion without stopping treatment to test a theory.

New suicidal thoughts, severe agitation or a shift toward unusually elevated mood needs prompt clinical attention. Immediate danger requires emergency support. Prescribing information also describes uncommon but serious problems such as serotonin syndrome, low sodium, seizures and significant bleeding. These risks need to be interpreted alongside the person’s health and other treatment. [6]

Fever with confusion and marked muscle stiffness, a seizure, collapse or serious breathing difficulty warrants urgent assessment. Tell the treating team about recent starts, stops and dose changes. Do not assume a severe reaction is a normal adjustment period, and do not use a comparison page to decide how to manage it at home.

Other serotonergic medicines and MAO inhibitors require particular caution. A pharmacist should check pain medicines, cough remedies, supplements and prescriptions from other clinicians. Citalopram also has interactions that can increase its concentration or add to QT-related risk. A medicine being available over the counter does not make the combination harmless. [4]

Tablets and liquids need their own instructions. Citalopram oral drops, for example, should not be substituted using an assumed volume or drop count. Liquid concentration and bioavailability can affect a conversion. Ask the pharmacist to verify the actual product when changing formulation, traveling or obtaining a prescription from a different supplier.

Agree what improvement would look like before concluding that one medicine has failed. Relevant outcomes may include mood, panic frequency, intrusive symptoms, attendance at therapy and ordinary responsibilities. Record adherence and adverse effects, because an inconsistent course caused by intolerable symptoms is different from an adequate course with no benefit.

Review timing depends on the diagnosis, risk and stage of treatment. Do not wait for a routine appointment when safety deteriorates. Equally, a single difficult day does not establish that a previously helpful treatment has stopped working. A review should consider sleep, substance use, physical illness, stress and psychological care as well as the medicine.

SSRIs can cause withdrawal symptoms after reducing or stopping treatment. That does not mean they have the same addiction pattern as medicines sought for intoxication. Dizziness, sensory disturbances, sleep problems and anxiety after a change need assessment alongside possible recurrence of the original condition. The timeline can be helpful but is not a definitive self-diagnosis.

A planned reduction should be individualized and reviewed. Neither sertraline nor citalopram should be stopped abruptly simply because a comparison suggests another option might fit better. Read antidepressant withdrawal and discuss any previous difficulties with reductions before agreeing a new plan.

A switch can involve withdrawal effects, interactions and a period before the new treatment’s benefit is clear. The method depends on the actual medicines and circumstances. Do not combine leftover supplies or match tablet strengths. Ask who will monitor the change, how prescriptions will be coordinated and what to do if symptoms worsen.

Neither medicine is a stand-alone alcohol, opioid or sedative detox treatment. Both may be considered within coordinated care for a genuine co-occurring mental-health condition. Tell the team about alcohol and other substances, including recent withdrawal. Treatment planning should avoid both overlooking depression and assuming every early withdrawal symptom proves a separate psychiatric diagnosis.

Start by writing the specific reason for comparing the medicines. Is the concern persistent depression, an anxiety diagnosis, a new heart condition, an adverse effect or an inconvenient formulation? Without that question, a consultation can become a list of possible benefits and harms with no clear decision. Bring the previous treatment history, including what helped and why earlier medicines were stopped.

Prepare a short account of actual use. Missed doses, uncertainty about the label or difficulty tolerating a side effect can change the interpretation of apparent nonresponse. These are practical treatment problems, not character flaws. Ask the clinician to explain which information would change the recommendation and whether further assessment is needed before a switch is considered. A good plan can include maintaining the current medicine while a relevant physical-health question is clarified.

At the end of the review, confirm what will happen next and who is responsible. The written plan should name the medicine and formulation, the agreed monitoring and the timing of follow-up. It should also explain how to obtain advice if symptoms change before the appointment. Where a heart specialist, primary-care clinician and psychiatrist are involved, ask how their recommendations will be shared. The patient should not have to reconcile conflicting prescriptions alone.

Is sertraline stronger than citalopram?

Tablet numbers are not directly comparable. Response varies, and a medicine’s suitability depends on the condition and the individual. There is no universal strength ranking that determines the best prescription.

Should someone with heart disease automatically switch?

No. Heart history is a reason for a focused review, including other medicines and monitoring. Any change should be planned with the clinician who knows the current treatment and the cardiac condition.

Can one help when the other has not?

Possibly, but the reason for limited benefit should be reviewed first. Diagnosis, treatment duration, actual use, adverse effects and other forms of care all influence the next step.

What questions should I bring?

Ask which diagnosis is being targeted, what risks distinguish the options, how benefit will be measured and how any future change will be managed. The medication-review checklist offers a practical starting point.

• [1] NHS: Sertraline.
• [2] NHS: Citalopram.
• [3] DailyMed: Sertraline hydrochloride prescribing information.
• [4] MHRA: Citalopram and escitalopram, QT interval prolongation.
• [5] NHS Specialist Pharmacy Service: Antidepressants in coronary heart disease.
• [6] DailyMed: Citalopram prescribing information.